CING Rasio cepet Cingulate Inc

Global instability and supply chain disruptions create risks for international drug trials, leading to financial losses. Current development of extended-release ADHD medications remains under FDA oversight, limiting access to the mass market. However, the unique CTR precision release technology protects Cingulate Inc. (CING) from generic competition. This chart reflects the current share price on GURU.Markets at 3.53.

For Cingulate Inc. (CING), which relies on external contractors for drug development, immediate solvency excluding inventories is critical. An analysis of the quick liquidity structure allows for an assessment of cash and accounts receivable relative to short-term liabilities, confirming the company's ability to fund CRO/CMO outsourcing and ensuring the stability of market value amid operational dependence on vendors.